Unlock stock picks and a broker-level newsfeed that powers Wall Street.
What Type Of Shareholders Make Up Shield Therapeutics plc's (LON:STX) Share Registry?

In This Article:

If you want to know who really controls Shield Therapeutics plc (LON:STX), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that have been privatized tend to have low insider ownership.

With a market capitalization of UK£78m, Shield Therapeutics is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about Shield Therapeutics.

View our latest analysis for Shield Therapeutics

ownership-breakdown
AIM:STX Ownership Breakdown January 27th 2022

What Does The Institutional Ownership Tell Us About Shield Therapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in Shield Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Shield Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
AIM:STX Earnings and Revenue Growth January 27th 2022

Shield Therapeutics is not owned by hedge funds. The company's largest shareholder is Inventages Venture Capital Investment Inc., with ownership of 26%. Aop Orphan International Ag is the second largest shareholder owning 13% of common stock, and Jupiter Fund Management Plc holds about 5.6% of the company stock.

To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Shield Therapeutics

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.